Peripheral GFAP Predicts Incident Dementia in Parkinson’s Disease

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Importance Dementia is a common and disabling complication of Parkinson disease (PD). Blood-based biomarkers that identify individuals at higher risk of future dementia could improve prognostication and trial stratification. Objective To determine whether blood-based proteins are associated with future risk of dementia in PD. Design, Setting, and Participants Prospective longitudinal cohort study with discovery and replication analyses in the Oxford Parkinson’s Disease Centre (OPDC) Discovery cohort and the Parkinson’s Progression Markers Initiative (PPMI). A total of 1,335 participants with PD and 431 healthy controls, with serum, plasma, or cerebrospinal fluid proteomic data and follow-up of up to 12 years, were included. Main Outcomes and Measures Incident dementia, defined using a composite of MoCA scores, MDS-UPDRS items, and clinician diagnosis. Associations between baseline protein levels and time to dementia were evaluated. Results Among 1,335 participants with PD, 168 developed incident dementia across cohorts (OPDC Discovery [serum], n = 108; PPMI Project 293 [plasma], n = 23; PPMI Project 181 [CSF], n = 37). In the OPDC cohort, GFAP was the only protein (of 5,408 tested) significantly associated with incident dementia (HR = 2.43; 95% CI: 1.79–3.30; p-adjust =1.35 × 10 -4 ). Higher GFAP tertiles were associated with greater cumulative dementia incidence. Findings were replicated in the PPMI plasma project (HR = 2.42; 95% CI: 1.12–5.22; p = 0.024) but not in the CSF project (HR = 0.96; 95% CI: 0.66–1.39; p = 0.82). Higher baseline GFAP was significantly associated with lower baseline cognitive performance and greater longitudinal cognitive decline but no significant association with motor progression. In both cohorts, GFAP levels increased over time but showed no group-level differences. Conclusions and Relevance Circulating GFAP is a robust and reproducible predictor of future dementia in PD, detectable early in the disease course. While the lack of differential longitudinal trajectories between PD patients with and without dementia suggests that GFAP does not act as a dynamic marker of cognitive decline, its relative stability supports its role as an early indicator of underlying biological vulnerability or subclinical pathology. These findings support serum GFAP as a promising, accessible biomarker for early dementia risk stratification. Key Points Question Are any blood-based proteins associated with future risk of dementia in Parkinson’s disease? Findings In this prospective longitudinal cohort study of 1,335 participants with Parkinson’s disease, baseline glial fibrillary acidic protein was the only one of 5,408 proteins associated with incident dementia in the discovery cohort and was replicated in an independent plasma cohort, but not in cerebrospinal fluid. Meaning Peripheral glial fibrillary acidic protein may help identify people with Parkinson’s disease at higher risk of future dementia early in the disease course.

Related topics